Skip To Main Content
Anand Patel on Muck Rack

Anand Patel

As seen in: Amazon Web Services, Medium, MSN India, Daily Mail, Nature, The Times of India, Wiley Online Library, NDTV, The BMJ, ACS Publications and

Get in touch with Anand

Contact Anand, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach

|
By Raajit Rampal, Richard Winneker, Andrew Kuykendall, Laura C. Michaelis, Ghaith Abu-Zeinah, Steffen Koschmieder, Jan Philipp Bewersdorf, Zi Yun Ng, Gabriella Hobbs, Bridget Marcellino, Linda Resar, Joseph M. Scandura, Anand Patel, John Mascarenhas, Aaron Gerds, Douglas Tremblay, Andriy Derkach, Florian H. Heidel, Shane Mayack
| Nature Verified
Introduction The development of precision medicine approaches in oncology has revolutionized clinical practice. Although definitions of precision medicine may vary, it is reasonably defined as the use of biomarkers to select a treatment approach for a patient to optimize the chance of response [1,2,3].
Open in Who Shared Issue with article?

Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography–segmentation and a geriatric assessment

|
By Samuel J. Yates, Lauren Miller, John Cursio, Claire Wild, Megan Huisingh-Scheetz, Michael Zhang Verified, Nicholas Feinberg, Karteek Popuri, Hamed R. Youshanlouei, Jamie Mathews, Caner Saygin, Anand Patel, Olatoyosi Odenike, Richard Larson, Mariam T. Nawas, Wendy Stock, Elizabeth Terman, Varun Akella, Afsheen Noorani
| Nature Verified
Introduction Less intensive treatment (LIT) regimens, primarily the combination of a hypomethylating agent and venetoclax (HMA+venetoclax), have replaced intensive regimens for the frontline treatment of AML for most older adults [1]. However, poor treatment tolerance remains an issue for older adults receiving LIT. Older adults receiving HMA+venetoclax continue to experience high 60- and 90-day mortality (10–20%), with frequent dose reductions and treatment discontinuations [2].
Open in Who Shared Issue with article?

Choice of hypomethylating agent for newly diagnosed TP53 -mutant acute myeloid Leukemia: a COMMAND registry study

|
By Talha Badar, James M. Foran, Chenyu Lin, Anand Patel, Yu-Hung Wang, Mahesh Kumar, Rory M. Shallis, Kendall Diebold, Alexander Coltoff, Aaron Goldberg, Jan P. Bewersdorf, Kenneth M. Zabel, Charles E. Foucar, Yasmin Abaza, S. Murthy, Neil Palmisiano, Adam Duvall Verified, Vamsi Kota, Shyam Patel, Amer M Zeidan, Hemant S. Murthy, Mohamed A. Kharfan-Dabaja, Ehab Atallah, Mark Litzow
| Nature Verified
Abstract Although azacitidine (AZA) and decitabine (DEC) demonstrate comparable efficacy in AML, prior data suggest that DEC may induce deeper TP53 mutation clearance and higher response rates; however, direct comparisons in TP53-mutant (TP53-MT) AML are lacking. We conducted a large multicenter retrospective analysis to compare outcomes between DEC- and AZA-based induction, including combinations with venetoclax (VEN).
Open in Who Shared Issue with article?
See all 921 licensed articles (948 Total)